50. Eur J Cancer Care (Engl). 2018 Mar;27(2):e12834. doi: 10.1111/ecc.12834.RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H.,etÂ al.Telford C(1).Author information: (1)Health Economics & Payer Analytics, AstraZeneca Pharmaceuticals, Gaithersburg,MD, USA.Comment on    Eur J Cancer Care (Engl). 2017 Nov;26(6):null.DOI: 10.1111/ecc.12834 PMID: 29575265  [Indexed for MEDLINE]